Volitionrx LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX

30 Apr 2026

VNRX

10-K/A: VolitionRx Files 10-K/A for Governance and Proxy Updates

VolitionRx Limited filed an amendment to its 2025 Annual Report to include required Part III information and updated Sarbanes-Oxley certifications.

AMEX

31 Mar 2025

VNRX

Volitionrx LTD

10-K: VolitionRx Appoints Timothy Still as Non-Executive Chairman, Outlines Director Compensation and Governance

VolitionRx Limited appoints Timothy Still as non-executive Chairman of the Board, detailing his responsibilities, compensation, and the company's commitment to indemnification and insurance.

AMEX

25 Mar 2024

VNRX

Volitionrx LTD

10-K: VolitionRx Limited 2023 Annual Report: Focus on Commercialization and Epigenetic Innovation

VolitionRx's 2023 annual report highlights the company's transition towards commercialization of its Nu.Q technology, alongside continued research and development in epigenetics.